【热门产品推介】卡利尤单抗，Camidanlumab， AntibodySystem Laboratories

卡利尤单抗，Camidanlumab，CAS:921618-45-3， AntibodySystem Laboratories

 货号：DHB95803

产品链接：http://www.atagenix.com/product_detail-75440.html

别名：ADCT-301(unconjugated), HuMax-TAC-ADC, CAS: 921618-45-3

简介：

Camidanlumab (HuMax-TAC) 是一种 CD25 单克隆抗体。Camidanlumab 靶向细胞表面抗原 CD25，该抗原在多种血液肿瘤中过度表达，在正常组织中表达有限。 Camidanlumab 可用于合成抗体药物偶联物 (ADCs)，研究包括淋巴瘤和白血病在内的多种疾病。

货号：DHB95803

产品品牌：Antibodysystem

通用名：Camidanlumab

纯度：>95% by SDS-PAGE.

浓度：1mg/ml

Formulationicon：

0.01M PBS, pH 7.4.

内毒素：Please contact with the lab for this information.

别名：ADCT-301(unconjugated), HuMax-TAC-ADC

靶点;物种：Human CD25/IL2RA

种类：Homo sapiens

受体鉴定：IgG1-kappa

化学信息：CAS: 921618-45-3

存储条件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

参考文献：

CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma. PMID: 36074313
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. PMID: 34048682
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. PMID: 33492560
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. PMID: 32521310
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. PMID: 32543981
Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate, Camidanlumab Tesirine. PMID: 35257078
Current salvage therapies in Hodgkin lymphoma. PMID: 35037568
Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. PMID: 36333463
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. PMID: 36333464
Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. PMID: 33602008
Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine. PMID: 36800311
The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates. PMID: 32669316
CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. PMID: 32912922
Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy. PMID: 36702422